Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

Figure 4

Mutant-TK mediated AKT signaling pathways are potently and globally suppressed by dual PI3K/MTOR inhibition. Immunoblotting of equally loaded whole cell extracts reveals strong consecutive suppression of AKT signaling pathways in the acute leukemia cell lines MOLM14 or K562, which harbor known autoactivating tyrosine kinase (TK) mutations (MOLM14: FLT3 ITD; K562: BCR/ABL1). TKI and specific MTORC1 inhibition by rapamycin reveal a differential inhibition profiles. Jurkat cells are used as positive controls for activated AKT signaling; PI3K-inhibited Jurkat cells (treated with LY294002) serve as negative controls. Actin blotting is used as a loading control.

Back to article page